Gefitinib (Iressa) and Erlotinib (Tarceva) are EGFR inhibitors that are used clinically for the treatment of advanced NSCLC, primarily that with EGFR mutations in the tyrosine kinase domains [13]–[16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.